Axsome Therapeutics (NASDAQ: AXSM) reported Q1 EPS of ($0.26), $1.03 better than the analyst estimate of ($1.29). Revenue for the quarter came in at $28.6 million versus the consensus estimate of $25.2 million.

Axsome believes that its current cash, along with the remaining committed capital from the $350 million term loan facility, is sufficient to fund anticipated operations into cash flow positivity, based on the current operating plan.

For earnings history and earnings-related data on Axsome Therapeutics (AXSM) click here.